Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Bayer

In these two podcast episodes, GI oncologists discuss the clinical cases of two patients with gastric and gastroesophageal (GE) cancer.

Episode 1 focuses on a patient with non-metastatic cancer, while Episode 2 looks at a metastatic case.

Listen to both podcast episodes or watch a video recording of the conversation for an update on:

  • Treatment sequences in gastric and gastroesophageal cancer
  • Practice-changing data and essential biomarker testing 
  • Near-future developments in the field

 

Dr. Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and oesophageal programme. His clinical and translational research is centred on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, co-chairs the NCI oesophagogastric task force, and is on the NCCN guideline committees for gastric and oesophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, the Degregorio Foundation, and The Gastric Cancer Foundation and Gateway for Cancer Research. He is active in gastric and oesophageal cancer outreach and patient advocacy.

Assoc. Prof. Samuel J Klempner has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, BMS, Coherus, Daiichi-Sankyo, Eli Lilly, Merck, Novartis, Nuvalent Therapuetics and Sanofi.

Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Dr Elizabeth Smyth has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants from Bristol-Myers Squibb and Astra Zeneca, personal fees from Amgen, Astellas, Astra Zeneca, Beigene, Bristol-Myers Squibb, Daiichi Sankyo, Merck, Mirati, Novartis, Pfizer, Viracta, and Zymeworks. Chair of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group (2024–26), and has been trustee of the UK & Ireland Oesophagogastric Cancer Group since 2022; and is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre

Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Bayer

In these two podcast episodes, GI oncologists discuss the clinical cases of two patients with gastric and gastroesophageal (GE) cancer.

Episode 1 focuses on a patient with non-metastatic cancer, while Episode 2 looks at a metastatic case.

Listen to both podcast episodes or watch a video recording of the conversation for an update on:

  • Treatment sequences in gastric and gastroesophageal cancer
  • Practice-changing data and essential biomarker testing 
  • Near-future developments in the field

 

Dr. Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and oesophageal programme. His clinical and translational research is centred on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, co-chairs the NCI oesophagogastric task force, and is on the NCCN guideline committees for gastric and oesophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, the Degregorio Foundation, and The Gastric Cancer Foundation and Gateway for Cancer Research. He is active in gastric and oesophageal cancer outreach and patient advocacy.

Assoc. Prof. Samuel J Klempner has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, BMS, Coherus, Daiichi-Sankyo, Eli Lilly, Merck, Novartis, Nuvalent Therapuetics and Sanofi.

Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Dr Elizabeth Smyth has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants from Bristol-Myers Squibb and Astra Zeneca, personal fees from Amgen, Astellas, Astra Zeneca, Beigene, Bristol-Myers Squibb, Daiichi Sankyo, Merck, Mirati, Novartis, Pfizer, Viracta, and Zymeworks. Chair of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group (2024–26), and has been trustee of the UK & Ireland Oesophagogastric Cancer Group since 2022; and is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre

Programme summary
Listen to the podcast now
Other episodes of this series
Gastroesophageal Cancer: Clinical Case Discussions

Gastroesophageal Cancer: Clinical Case Discussions

Episode 1: Non-metastatic cancer patient case

Gastroesophageal Cancer: Clinical Case Discussions

Gastroesophageal Cancer: Clinical Case Discussions

Episode 2: Metastatic cancer patient case

Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Other episodes of this series
Gastroesophageal Cancer: Clinical Case Discussions

Gastroesophageal Cancer: Clinical Case Discussions

Episode 1: Non-metastatic cancer patient case

Gastroesophageal Cancer: Clinical Case Discussions

Gastroesophageal Cancer: Clinical Case Discussions

Episode 2: Metastatic cancer patient case

Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology Endocrinology Rare diseases 
Exploring the role of targeted radiopharmaceutical treatment in NETs

PRRT and emerging strategies in neuroendocrine tumours

Experts
Prof. Ken Herrmann, Dr Heloisa Soares, Oncology Brothers (Moderators)
Endorsed by
NANETS
CommNETs Neuroendocrine Cancer UK
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from ITM.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
ZERO Urobel VZW | ASBL
EAUN
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
conference-update Conference update
Oncology 
Oncogene-addicted NSCLC highlights from WCLC 2025

Expert insights on the latest data in oncogene-addicted non-small cell lung cancer 

Experts
Dr Devika Das
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
Lung Cancer Research Foundation
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Understanding the BRAFV600E testing and treatment landscapes in NSCLC

Two perspectives, one aim: A pathologist and a medical oncologist in discussion

Experts
Assoc. Prof. Umberto Malapelle, Prof. Nicolas Girard
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.